Tue, Oct 21, 2014, 12:41 AM EDT - U.S. Markets open in 8 hrs 49 mins

Recent

% | $
Quotes you view appear here for quick access.

ZIOPHARM Oncology, Inc. Message Board

fkofranklin1 1 post  |  Last Activity: Oct 17, 2014 10:22 PM Member since: Oct 27, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Overall Survival

    by gophr4life Oct 17, 2014 9:41 AM
    fkofranklin1 fkofranklin1 Oct 17, 2014 10:22 PM Flag

    The issue isn't that they can't share but they are choosing to wait for OS data where half of the patients succumb to the disease on both arms. The real issue is whether the control arm has already reached the half way point for OS. I doubt that it did or else the management would have stated it so the safer conservative interpretation is that both arms the patients are living longer than historical so don't get your hopes up for any statistical difference in OS though it would be great if it did. Just remember that this trial met the primary end point and some of the secondary end points remarkably well and a good safety profile compared to Doxil. Also, I think that this trial isn't blinded so the investigators must be seeing the data already so their downplaying the expectations may mean something.

    Sentiment: Buy

ZIOP
2.47-0.05(-1.98%)Oct 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Apple Inc.
NasdaqGSMon, Oct 20, 2014 4:00 PM EDT
NCR Corp.
NYSEMon, Oct 20, 2014 4:02 PM EDT